Identifying Patients and Families at Risk for Cancer
With approximately 5% to 10% of cancers attributable to a hereditary cancer predisposition syndrome, identifying those patients with cancer who are at risk has significant benefit both to patients and their relatives.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo